Skip to main content

Table 1 Patients and transplantation characteristics

From: Multicenter phase ii study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)

Variables

N

%

Patients

508

 

Male

294

57.9

Female

214

42.1

Median age, years (range)

36 (15–62)

 

15-39

313

61.6

≥40

195

38.4

Disease

  

AML

231

45.5

CR

188

37.0

PR

2

0.4

NR

41

8.1

ALL

86

16.9

CR

80

15.7

NR

6

1.2

CML

156

30.7

CP

127

25.0

AP

10

2.0

BC

19

3.7

MDS-RAEB

35

6.9

Disease stage

  

Non-advanced

441

86.8

Advanced

67

13.2

Donor-recipient gender

  

Female–male

140

27.6

other

368

72.4

Stem cell sources

  

PB + BM

250

49.2

PB

258

50.8

ABO blood group status

  

Match

305

60.0

Mismatch

203

40.0

MMF Dose

  

0.5 g/d

151

29.7

1.0 g/d

357

70.3

Conditioning regimens

  

BuCy

347

68.3

TBICy

26

5.1

BuFlu

135

26.6

  1. AML, acute myeloid leukemia; CR, complete remission; PR, partial remission; NR, nonremission; ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia; CP, chronic phase; AP, accelerated phase; BC, blast crisis; MDS, myelodysplastic syndrome; RAEB, refractory anemia with excess blasts; Non-advanced stage, including acute leukemia (AL) in CR, CML in CP and AP, MDS-RAEB, Advanced stage, including AL in NR and CML in BC, PB, peripheral blood; BM, bone marrow; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; MMF, mycophenolate mofetil, Flu, fludarabin.